1.Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression.
Eun Jung LIM ; Sun Hye LEE ; Jin Gu LEE ; Jae Ryong KIM ; Sung Su YUN ; Suk Hwan BAEK ; ChuHee LEE
Experimental & Molecular Medicine 2007;39(2):239-245
Unmethylated CpG oligodeoxynucleotides (CpG ODNs) activate immune cells to produce immune mediators. This study demonstrates that in murine macrophage RAW 264.7 cells, CpG ODN-mediated matrix metalloproteinase-9 (MMP-9) expression is regulated at transcriptional level and requires de novo protein synthesis. Inhibition of ERK and p38 MAPK, but not JNK, results in significant decrease of CpG ODN-induced MMP-9 expression. We found that endosomal maturation inhibitors, chloroquine and bafilomycin A, block CpG ODN-induced ERK and p38 MAPK activation and the subsequent MMP-9 expression. We also observed that CpG ODN induces NF-kappa B activation and NF-kappa B is a downstream target of p38 MAPK. Taken together, our data demonstrate that CpG ODN triggers MMP-9 expression via TLR-9 dependent ERK and p38 MAPK activation followed by NF-kappa B activation.
Animals
;
Cell Line
;
Enzyme Activation/drug effects
;
Enzyme Induction/drug effects
;
Matrix Metalloproteinase 9/*biosynthesis
;
Mice
;
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors/metabolism
;
Mitogen-Activated Protein Kinase 3/antagonists & inhibitors/metabolism
;
Mitogen-Activated Protein Kinases/*metabolism
;
NF-kappa B/*metabolism
;
Oligodeoxyribonucleotides/*pharmacology
;
Signal Transduction/drug effects
;
Toll-Like Receptor 9/antagonists & inhibitors/*metabolism
;
p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism
2.Advances in the study of inhibitors of kinases and nuclear factors for treating allergic asthma.
Ren-Ping LIU ; Ai-Min MENG ; Qi HOU
Acta Pharmaceutica Sinica 2012;47(6):689-695
Currently, about 300 million people worldwide are affected by asthma. Most of these sufferers inhale immunosuppressants (ie corticosteroids) and beta-adrenergic receptor agonists for their asthma treatment. However, about 5%-10% of patients of asthma have poor response to such treatment. Investigation of kinase signaling pathway and nuclear transcription factor as a target molecule in the treatment of allergic asthma has been the concern of scholars home and abroad. This paper reviewed inhibitors of kinase signaling pathway and nuclear transcription factors for the treatment of asthma.
Animals
;
Asthma
;
drug therapy
;
enzymology
;
Humans
;
Mitogen-Activated Protein Kinases
;
antagonists & inhibitors
;
Phosphatidylinositol 3-Kinase
;
antagonists & inhibitors
;
Protein Kinase Inhibitors
;
therapeutic use
;
Protein-Tyrosine Kinases
;
antagonists & inhibitors
;
metabolism
;
Signal Transduction
;
Transcription Factors
;
antagonists & inhibitors
3.C-jun N-terminal kinase-mediated signaling is essential for Staphylococcus aureus-induced U937 apoptosis.
Jia-he WANG ; Bo YU ; Hui-yan NIU ; Hui LI ; Yi ZHANG ; Xin WANG ; Ping HE
Chinese Medical Sciences Journal 2009;24(1):26-29
OBJECTIVETo investigate the effect of SP600125, a specific c-jun N-terminal protein kinase (JNK) inhibitor, on Staphylococcus aureus (S. aureus)-induced U937 cell death and the underlying mechanism.
METHODSThe human monocytic U937 cells were treated with S. aureus at different time with or without SP600125. Cell apoptosis was analyzed by flow cytometry. JNK, Bax, and caspase-3 activities were detected by Western blotting.
RESULTSS. aureus induced apoptosis in cultured U937 cells in a time-dependent manner. Expression of Bax and phospho-JNK significantly increased in S. aureus-treated U937 cells, and the level of activated caspase-3 also increased in a time-dependent manner. Inhibition of JNK with SP600125 significantly inhibited S. aureus-induced apoptosis in U937 cells.
CONCLUSIONSS. aureus can induce apoptosis in U937 cells by phosphorylation of JNK and activation of Bax and caspase-3. SP600125 protects U937 cells from apoptosis induced by S. aureus via inhibiting the activity of JNK.
Anthracenes ; pharmacology ; Apoptosis ; physiology ; Caspase 3 ; metabolism ; Humans ; JNK Mitogen-Activated Protein Kinases ; metabolism ; Macrophages ; cytology ; metabolism ; microbiology ; Mitogen-Activated Protein Kinase 8 ; antagonists & inhibitors ; metabolism ; Mitogen-Activated Protein Kinase 9 ; antagonists & inhibitors ; metabolism ; Phosphorylation ; drug effects ; Protein Kinase Inhibitors ; pharmacology ; Signal Transduction ; physiology ; Staphylococcus aureus ; physiology ; U937 Cells ; bcl-2-Associated X Protein ; metabolism
4.Regulative function of extracelluar regulated protein kinases and telomerase in apoptosis of hepatocarcinomatous cell SMMC-7721.
Deng Ju LI ; Yao Zhen ZHANG ; Wen Jing CAO ; Wei HUANG ; Wen Li LIU
Chinese Journal of Hepatology 2002;10(4):287-288
OBJECTIVETo study the changes of telomerase activity and protein expression of phosphorylated (activated) extracellular regulated protein kinases (ERK1 and ERK2) in the course of inhibiting hepatocarcinomatous cell proliferation and inducing cell apoptosis by three kinds of chemotherapy drugs: Harringtonine (HRT), Vincristine (VCR), and Etoposide (Vp16). To discuss the regulative function to hepatocarcinomatous cell apoptosis and interrelation of telomerase and ERK.
METHODSCytotoxicity assay, flow cytometry analysis, telomerase repeat amplification protocol assay (TRAP), bioluminescence analysis, and western blot were used in this experiment.
RESULTSHRT, VCR, and Vp16 could inhibit cell proliferation (0.28% 0.08%, 0.25% 0.16%, 0.24% 0.11%), induce apoptosis (21.12%, 28.83%, 12.30%), inhibit telomerase activity, and down-regulate the protein expression of phosphorylated ERK.
CONCLUSIONSIt might be through ERK signal transduction pathways that chemotherapy drugs down-regulate telomerase activity and induce apoptosis.
Apoptosis ; Carcinoma, Hepatocellular ; drug therapy ; enzymology ; pathology ; Etoposide ; pharmacology ; Harringtonines ; pharmacology ; Humans ; Liver Neoplasms ; drug therapy ; enzymology ; pathology ; Mitogen-Activated Protein Kinase 1 ; antagonists & inhibitors ; physiology ; Mitogen-Activated Protein Kinase 3 ; Mitogen-Activated Protein Kinases ; antagonists & inhibitors ; physiology ; Signal Transduction ; Telomerase ; physiology ; Tumor Cells, Cultured ; Vincristine ; pharmacology
5.Expression and Regulation of Endothelial Nitric Oxide Synthase by Vascular Endothelial Growth Factor in ECV 304 Cells.
Jong Seon PARK ; Gu Ru HONG ; Suk Whan BAEK ; Dong Gu SHIN ; Young Jo KIM ; Bong Sup SHIM
Journal of Korean Medical Science 2002;17(2):161-167
Nitric oxide (NO) seems to play a pivotal role in the vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation. This study was designed to investigate the role and intracellular signal pathway of endothelial nitric oxide synthase (eNOS) activation induced by VEGF. ECV 304 cells were treated with betaVEGF(165) and then cell proliferation, eNOS protein and mRNA expression levels were analyzed to elucidate the functional role of eNOS in cell proliferation induced by VEGF. After exposure of cells to betaVEGF(165) , eNOS activity and cell growth were increased by approximately two-fold in the betaVEGF(165) -treated cells compared to the untreated cells. In addition, VEGF stimulated eNOS expression at both the mRNA and protein levels in a dose-dependent manner. Phosphatidylinositol-3 kinase (PI-3K) inhibitors were used to assess PI-3K involvement in eNOS regulation. LY294002 was found to attenuate VEGF-stimulated eNOS expression. Wortmannin was not as effective as LY294002, but the reduction effect was detectable. Cells activated by VEGF showed increased ERK1/2 levels. Moreover, the VEGF-induced eNOS expression was reduced by the PD98059, MAPK pathway inhibitor. This suggests that eNOS expression might be regulated by PI-3K and the ERK1/2 signaling pathway. In conclusion, betaVEGF(165) induces ECV 304 cell proliferation via the NO produced by eNOS. In addition, eNOS may be regulated by the PI-3K or mitogen-activated protein kinase pathway.
1-Phosphatidylinositol 3-Kinase/*antagonists & inhibitors
;
Cell Division/drug effects
;
Cell Line
;
Endothelial Growth Factors/*metabolism/pharmacology
;
Endothelium, Vascular/cytology
;
*Gene Expression Regulation, Enzymologic
;
Lymphokines/*metabolism/pharmacology
;
MAP Kinase Signaling System
;
Mitogen-Activated Protein Kinase 1/*antagonists & inhibitors
;
Mitogen-Activated Protein Kinase 3
;
Mitogen-Activated Protein Kinases/*antagonists & inhibitors
;
Nitric Oxide Synthase/*genetics/metabolism
;
Nitric Oxide Synthase Type III
;
Signal Transduction
;
Vascular Endothelial Growth Factor A
;
Vascular Endothelial Growth Factors
6.Rhein inhibits transforming growth factor beta1 induced plasminogen activator inhibitor-1 in endothelial cells.
Jiaming ZHU ; Zhihong LIU ; Haidong HUANG ; Zhaohong CHEN ; Leishi LI
Chinese Medical Journal 2003;116(3):354-359
OBJECTIVESTo investigate the effect of rhein on endothelial plasminogen activator inhibitor-1 (PAI-1) mRNA expression and protein production induced by transforming growth factor beta1 (TGFbeta1), and to explore the mechanism of the protective action of rhein on endothelial cells.
METHODSA human umbilical endothelium derived cell line (ECV-304) from ATCC was used in this study. The PAI-1 mRNA expression and protein synthesis in the endothelial cells were detected by Northern blot and flow cytometry analysis, respectively. The activity of phospho-p44/p42 MAP kinase induced by TGFbeta1 was determined by immunoprecipitation analysis and western blot.
RESULTSTGFbeta1 rapidly increased PAI-1 mRNA expression in the endothelial cells, and this effect lasted at least 24 hours. The upregulation of PAI-1 mRNA expression induced by TGFbeta1 in endothelial cells was inhibited by rhein in a dose-dependent manner. In addition, rhein inhibited endothelial PAI-1 protein production. Further study revealed that rhein had a significant inhibitory effect on the activity of phospho-p44/p42 MAP kinase induced by TGFbeta1 in human endothelial cells.
CONCLUSIONSOur results showed that rhein may have a protective effect on the endothelial dysfunction by inhibiting overexpression of PAI-1, indicating a way for the treatment of vascular diseases.
Anthraquinones ; pharmacology ; Cells, Cultured ; Dose-Response Relationship, Drug ; Endothelium, Vascular ; drug effects ; metabolism ; Humans ; Mitogen-Activated Protein Kinase 1 ; metabolism ; Mitogen-Activated Protein Kinase 3 ; Mitogen-Activated Protein Kinases ; metabolism ; Plasminogen Activator Inhibitor 1 ; biosynthesis ; genetics ; RNA, Messenger ; analysis ; Transforming Growth Factor beta ; antagonists & inhibitors ; Transforming Growth Factor beta1
7.Mechanism of inhibitory effect of P7 on 3T3 cell proliferation induced by basic fibroblast growth factor.
Cong WANG ; Shao-qiang LIN ; Xiao-kun LI ; Xiao-ping WU
Acta Pharmaceutica Sinica 2010;45(3):314-317
To investigate the mechanism of inhibitory effect of a novel bFGF antagonist peptide isolated from the phage display random heptapeptide library on cell proliferation induced by basic fibroblast growth factor. The effect of P7 on cell morphology was observed under an inverted microscope. Flow cytometry was applied to analyze the effect of P7 on cell cycle progress of bFGF-stimulated cells. The effect of P7 on bFGF-induced activation of MEK and Erk1/2 in MAPK pathway was detected by Western blotting. The results showed that no significant cell morphology change was observed in the range of detected concentrations of P7. Cell cycle analysis showed that P7 decreased S-phase cell population and arrested cell cycle at the G0/G1 phase of bFGF-stimulated cells. The results of MAP kinase activation assay indicated that P7 decreased bFGF-induced MEK and Erk1/2 phosphorylation in a dose-dependent manner. P7 inhibited proliferation of bFGF-stimulated Balb/c 3T3 cells possibly via cell cycle arrest at the G0/G1 phase and down-regulation of signal molecular activation in MAPK pathway.
Animals
;
BALB 3T3 Cells
;
Cell Cycle
;
drug effects
;
Cell Proliferation
;
drug effects
;
Fibroblast Growth Factor 2
;
antagonists & inhibitors
;
pharmacology
;
MAP Kinase Kinase Kinases
;
metabolism
;
MAP Kinase Signaling System
;
drug effects
;
Mice
;
Mice, Inbred BALB C
;
Mitogen-Activated Protein Kinase 1
;
metabolism
;
Mitogen-Activated Protein Kinase 3
;
metabolism
;
Peptides
;
pharmacology
;
Phosphorylation
;
Protein Binding
8.Inhibitory effect of Hsp70 on angiotensin II-induced vascular smooth muscle cell hypertrophy.
Ying ZHENG ; Chang Nim IM ; Jeong Sun SEO
Experimental & Molecular Medicine 2006;38(5):509-518
Angiotensin II (Ang II), which is an important mediator of both vascular responsiveness and growth, has been shown to induce vascular smooth muscle cell (VSMC) hypertrophy via the activation of a complex series of intracellular signaling events. Heat shock protein 70 (Hsp70) has recently been shown to protect against Ang II-induced hypertension. In this study, we tested the hypothesis that Hsp70 can protect VSMC from Ang II-induced hypertrophy. We treated VSMCs with Ang II to induce hypertrophy and to activate MAPK signaling pathway. We observed that the augmentation of Hsp70 expression inhibited Ang II-stimulated VSMC hypertrophy. This inhibitory effect of Hsp70 appears to be partly due to extracellular signal-regulated kinase (ERK1/2) inactivation, which in turn, may possibly result from the accumulation of MAP kinase phosphatase-1 (MKP-1).
Rats, Sprague-Dawley
;
Rats
;
RNA, Small Interfering/pharmacology
;
Protein-Tyrosine-Phosphatase/metabolism/physiology
;
Phosphoprotein Phosphatase/metabolism/physiology
;
Muscle, Smooth, Vascular/*cytology/*drug effects
;
Mitogen-Activated Protein Kinase 3/antagonists & inhibitors
;
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors
;
Male
;
MAP Kinase Kinase 2/metabolism
;
MAP Kinase Kinase 1/metabolism
;
Immediate-Early Proteins/metabolism/physiology
;
Hypertrophy
;
HSP70 Heat-Shock Proteins/antagonists & inhibitors/*pharmacology
;
Flavonoids/pharmacology
;
Enzyme Stability/drug effects
;
Cells, Cultured
;
Cell Cycle Proteins/metabolism/physiology
;
Aorta/drug effects/pathology
;
Animals
;
Angiotensin II/*pharmacology
9.Arginine vasopressin stimulates proliferation of adult rat cardiac fibroblasts via protein kinase C-extracellular signal-regulated kinase 1/2 pathway.
Yan-Ping HE ; Lian-You ZHAO ; Qiang-Sun ZHENG ; Shao-Wei LIU ; Xiao-Yan ZHAO ; Xiao-Long LU ; Xiao-Lin NIU
Acta Physiologica Sinica 2008;60(3):333-340
Arginine vasopressin (AVP), a neurohormone and hemodynamic factor implicated in the pathophysiology of hypertension and congestive heart failure, can also act as a growth-stimulating factor. Our previous work demonstrated that AVP is a mitogen for neonatal rat cardiac fibroblasts (CFs). In the present study, we extended our investigations to adult rat CFs to explore whether AVP could induce adult rat CF proliferation and, if so, to identify the mechanism involved. Adult rat CFs were isolated, cultured and subjected to AVP treatment. DNA synthesis and cell cycle distribution were analyzed by [(3)H]-thymidine incorporation and flow cytometry. Cellular extracellular signal-regulated kinase 1/2 (ERK1/2) activity was measured by in vitro kinase assay using myelin basic protein (MBP) as a substrate. Protein expressions of total- and phospho-ERK1/2, p27(Kip1), cyclins D1, A, E were assessed by Western blot. The results showed that AVP stimulated DNA synthesis in adult rat CFs, and the effect was abolished by a V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin (0.1 μmol/L), but not by a V2 receptor antagonist, desglycinamide-[d(CH(2))(5), D-Ile(2), Ile(4), Arg8]-vasopressin (0.1 μmol/L). AVP induced an activation of ERK1/2, which could be mimicked by the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA, 30 nmol/L, 5 min), but abolished by depletion of PKC via chronic PMA incubation (2.5 μmol/L, 24 h). In addition, AVP down-regulated protein expression of p27(Kip1), increased protein expressions of cyclins D1, A and E, and induced cell cycle progression from G(0)/G(1) into S stage. Inhibition of ERK1/2 activation by PD98059 (30 μmol/L) abolished the effect of AVP on DNA synthesis, protein expressions of p27(Kip1), cyclins D1, A and E as well as cell cycle progression. These results suggest that AVP is also a growth factor for adult rat CFs. The mitogenic effect of AVP is mediated via V1 receptors and PKC-ERK1/2 pathway. Moreover, AVP modulates the expressions of cell cycle regulatory proteins p27(Kip1) and cyclins D1, A and E, which lie downstream of ERK1/2 activation, and induces cell cycle progression in adult rat CFs.
Animals
;
Antidiuretic Hormone Receptor Antagonists
;
pharmacology
;
Arginine Vasopressin
;
pharmacology
;
Cell Cycle
;
Cell Cycle Proteins
;
metabolism
;
Cell Proliferation
;
Fibroblasts
;
cytology
;
drug effects
;
Mitogen-Activated Protein Kinase 3
;
metabolism
;
Myocardium
;
cytology
;
Phosphorylation
;
Protein Kinase C
;
metabolism
;
Rats
;
Signal Transduction
;
Tetradecanoylphorbol Acetate
;
pharmacology
10.Beta-VLDL induced VLDL-R's up-regulation via PKC-ERK1/2 signal pathway.
Zhiguo LIU ; Yan WANG ; Shen QU ; Youmei FENG ; Fan WU ; Yiqiang ZONG ; Zechun ZHAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2004;24(4):314-317
To explore the intracellular signal pathways for beta-VLDL induced very low density lipoprotein receptor (VLDL-R) transcription up-regulation and their effects on lipid accumulation in macrophages, Western Blot was used to examine phosphorylated ERK1/2 protein and regulated effects by different singal kinase inhibitants. It was found that beta-VLDL induced an increase in ERK1/2 activity in a protein kinase C (PKC)-dependent manner in murine RAW264.7 macrophages. By using different protein kinases inhibitors or activators, it was observed that the effect of beta-VLDL induced VLDL receptor transcription, which was monitored by RT-PCR analysis of VLDL receptor mRNA, was not affected by the inhibitor of p38 kinase and cAMP analog, but extremely abolished by pretreating cells with PD98059, an inhibitor of ERK and GF 109203X, an inhibitor of PKC. These results demonstrated that the PKC-ERK1/2 cascade is the essential signaling pathway by which beta-VLDL activated VLDL-R mRNA expression. Inhibition of the ERK1/2 signaling cascade resulted in suppression of the cellular lipid accumulation induced by beta-VLDL in macrophages.
Cells, Cultured
;
Lipoproteins, VLDL
;
metabolism
;
Macrophages
;
cytology
;
metabolism
;
Mitogen-Activated Protein Kinase 1
;
metabolism
;
physiology
;
Mitogen-Activated Protein Kinase 3
;
metabolism
;
physiology
;
Protein Kinase C
;
antagonists & inhibitors
;
metabolism
;
Receptors, LDL
;
biosynthesis
;
genetics
;
Signal Transduction
;
Transcription Factors
;
metabolism
;
Transcription, Genetic
;
Up-Regulation